CA1330944C - Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers - Google Patents

Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers

Info

Publication number
CA1330944C
CA1330944C CA000608654A CA608654A CA1330944C CA 1330944 C CA1330944 C CA 1330944C CA 000608654 A CA000608654 A CA 000608654A CA 608654 A CA608654 A CA 608654A CA 1330944 C CA1330944 C CA 1330944C
Authority
CA
Canada
Prior art keywords
alkyl
cancer
mono
amino
topoisomerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000608654A
Other languages
English (en)
French (fr)
Inventor
De-Hua Li
C. Edgar Cook
Oi-Cheng Fang
Zhen-Guo Wang
Yue-Wei Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International Inc
Original Assignee
RTI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International Inc filed Critical RTI International Inc
Application granted granted Critical
Publication of CA1330944C publication Critical patent/CA1330944C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02—Saturated compounds containing hydroxy or O-metal groups
    • C07C62/06—Saturated compounds containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA000608654A 1988-08-24 1989-08-17 Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers Expired - Fee Related CA1330944C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23590388A 1988-08-24 1988-08-24
US07/235,903 1988-08-24

Publications (1)

Publication Number Publication Date
CA1330944C true CA1330944C (en) 1994-07-26

Family

ID=22887334

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000608654A Expired - Fee Related CA1330944C (en) 1988-08-24 1989-08-17 Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers

Country Status (10)

Country Link
EP (1) EP0431076B1 (OSRAM)
JP (1) JP2828295B2 (OSRAM)
KR (1) KR100187738B1 (OSRAM)
CN (1) CN1041204C (OSRAM)
AU (1) AU630374B2 (OSRAM)
CA (1) CA1330944C (OSRAM)
DE (1) DE68909947T2 (OSRAM)
DK (1) DK31391A (OSRAM)
TW (1) TW225990B (OSRAM)
WO (1) WO1990001937A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4201903B4 (de) * 1992-01-24 2004-04-15 Hermann P.T. Prof. Dr.Med. Ammon Pharmazeutische Verwendung von Boswelliasäuren
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
DE4445728A1 (de) 1994-12-21 1996-06-27 Simmet Th Prof Dr Verwendung von Boswelliasäure zur Behandlung von Hirntumoren
DE19531067A1 (de) † 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
AU4450600A (en) * 1999-04-30 2000-11-17 Sabinsa Corporation Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
WO2002085921A2 (de) * 2001-03-01 2002-10-31 Johann Jauch Einfaches verfahren zur synthese von boswelliasäuren und derivaten davon
CN1304007C (zh) * 2002-02-04 2007-03-14 中国医学科学院药物研究所 乙酰乳香酸在制备肿瘤转移抑制剂中的应用
US8028292B2 (en) 2004-02-20 2011-09-27 Sony Computer Entertainment Inc. Processor task migration over a network in a multi-processor system
BRPI0721676A2 (pt) * 2007-06-25 2013-10-15 Plant Bioscience Ltd Polinucleotídeo isolado, vetor, constructo de dna recombinante, método para transformar uma célula, célula transformada, método para produção de uma planta transgênica, planta transgênica, semente, célula hospedeira isolada, método de modificação do nível de expressão de um polipeptídeo e métodos para produção de uma planta
DE102008015607A1 (de) * 2008-03-26 2009-10-15 Universität Tübingen Verwendung von Boswelliasäuren und synthetischen Boswelliasäurederivaten zur Hemmung der mikrosomalen Prostaglandin E2 Synthase und des Cathepsin G
EP2408461B1 (de) 2009-03-17 2016-01-27 Ertelt, Herta Verfahren zur extraktion von pflanzlichen harzen sowie dadurch gewonnene extraktionsprodukte und deren verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501734A (en) * 1981-03-06 1985-02-26 Wakunaga Yakuhin Kabushiki Kaisha Promotion of absorption of drugs administered through the alimentary system

Also Published As

Publication number Publication date
CN1041204C (zh) 1998-12-16
EP0431076A1 (en) 1991-06-12
CN1043131A (zh) 1990-06-20
KR100187738B1 (ko) 1999-06-01
DE68909947T2 (de) 1994-02-24
JP2828295B2 (ja) 1998-11-25
KR900701280A (ko) 1990-12-01
EP0431076A4 (en) 1992-01-15
EP0431076B1 (en) 1993-10-13
AU4303389A (en) 1990-03-23
DK31391D0 (da) 1991-02-22
AU630374B2 (en) 1992-10-29
TW225990B (OSRAM) 1994-07-01
JPH04500209A (ja) 1992-01-16
DE68909947D1 (de) 1993-11-18
WO1990001937A1 (en) 1990-03-08
DK31391A (da) 1991-02-22

Similar Documents

Publication Publication Date Title
US5064823A (en) Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
AU2002245022B2 (en) Inhibition of NF-kappaB by triterpene compositions
CA1330944C (en) Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP3430322B2 (ja) スポンギスタチン５、７、８及び９
US5932613A (en) Anticancer agents
US7282593B2 (en) Withanamide and withanolide compositions and method of use thereof
Priebe Mechanism of action-governed design of anthracycline antibiotics: A" turn-off/turn-on" approach
CZ305745B6 (cs) Fosfolipidové deriváty kyseliny valproové a jejich směsi
JP2921990B2 (ja) コルヒチン誘導体及びその治療的利用
KR20210104830A (ko) 항노화를 위한 삼중 조합 요법
KR20210104829A (ko) 미토콘드리아를 표적화하고 암 줄기 세포를 사멸시키는 삼중 조합 요법
EP0815858B1 (en) Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-alpha-tocopherol ester
JPH09124489A (ja) インターロイキン−６生産抑制剤
Rozencweig et al. Phase I trial with 4′-deoxydoxorubicin (esorubicin)
CA2297149C (en) 13-deoxyanthracycline derivatives for treating cancer
Larsen Involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation
DE10111682B4 (de) Caloporosid-Derivate, Verfahren zu deren Herstellung und deren Verwendung
US5962515A (en) Process for isolation and synthesis of 1-(3,4 methylenedioxy-phenyl)-1E-tetradecene and its analogues and their activities against tumors and infections
KR102690860B1 (ko) 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
KR100466522B1 (ko) 항암활성을 갖는 ｊ 300 동충하초 추출물 및 이를함유하는 약제학적 조성물
KUNIMOTO et al. Biological activities of new anthracyclines containing fluorine, FAD 104 and its metabolites
Herscovici et al. Unsaturated epoxy-C-glycosides. A new class of antitumor compounds with DNA cleavage properties.
Mathe et al. Second-Generation Anthracyclines
das Graças Medeiros et al. Effects of treatment with mitoxantrone in combination with novobiocin, caffeine and ara-C on human lymphocytes in culture
JP2000239296A (ja) 細胞増殖抑制剤

Legal Events

Date Code Title Description
MKLA Lapsed